Ankylosing spondylitis – European Clinical Trials Information Network

A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Wed, 29 Apr 2026 15:07:43 +0000

This study is looking at a condition called radiographic axial spondyloarthritis, which is also known as ankylosing spondylitis. This is a type of arthritis that mainly affects the spine and can cause long-term pain and stiffness in the back. The inflammation can eventually lead to some of the small bones in the spine growing together. The study will test a medication called tulisokibart, which is also referred to by its code name MK-7240. This medication is given as an injection under the skin using a pre-filled device. Some people in the study will receive tulisokibart while others will receive a placebo.

The purpose of this study is to find out how well tulisokibart works compared to placebo in people with radiographic axial spondyloarthritis and to check how safe it is. The study will measure whether the medication helps reduce disease activity and improve symptoms. The main focus will be on checking how many people show significant improvement in their condition after 16 weeks of treatment.

During the study, participants will receive either tulisokibart or placebo through injections under the skin. The study team will regularly check how participants are doing by looking at various aspects of their condition, including back pain levels, how well they can perform daily activities, stiffness, fatigue, and overall quality of life. Some participants will also have imaging tests such as magnetic resonance imaging to see if there are changes in inflammation in the spine and joints. The study will also track any side effects or health problems that occur during the treatment period.

Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

Wed, 29 Apr 2026 14:25:02 +0000

This clinical trial is focused on studying the effects of a medication called Upadacitinib on a condition known as Axial Spondyloarthritis. Axial Spondyloarthritis is a type of arthritis that primarily affects the spine and the joints connecting the spine to the pelvis, causing pain and stiffness. The study aims to evaluate how well Upadacitinib works in reducing the signs and symptoms of this condition and to assess its safety for patients.

Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will also include a period where participants who respond well to the treatment will have their medication gradually withdrawn to observe if they can maintain remission, which is a state where symptoms are reduced or disappear.

The trial will be conducted over several weeks, with regular check-ups to monitor the participants’ health and the effects of the medication. The primary goal is to see if Upadacitinib can significantly improve the condition of patients with Axial Spondyloarthritis compared to those who receive the placebo. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Wed, 29 Apr 2026 14:23:29 +0000

This clinical trial is focused on studying the long-term safety of a treatment called Secukinumab, which is used for several conditions, including Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Severe Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, and Juvenile Idiopathic Arthritis. Secukinumab is administered as a solution for injection, and the study aims to evaluate its safety over a long period by monitoring any adverse events or reactions at the injection site.

The purpose of this study is to assess the long-term safety of Secukinumab in patients who have previously participated in a related study and are believed to benefit from continued treatment. Participants will receive Secukinumab through subcutaneous injections, which means the medication is injected under the skin. The study will continue for a period of up to 104 weeks, during which the safety of the treatment will be closely monitored by healthcare professionals.

Throughout the study, participants will be observed for any serious adverse events (SAEs) or adverse events (AEs), which are any unwanted effects that may occur during treatment. The study is open-label, meaning both the participants and the researchers know which treatment is being administered. This trial is designed to ensure that patients who benefit from Secukinumab can continue to receive it safely, with careful monitoring to manage any potential risks.